지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
The perception of the 20 adverse events of targeted therapy for metastatic renal cell carcinoma was compared among medical professionals. Thirty-seven oncologists, 167 nurses and 79 pharmacists participated in the survey, and the response rate was 61.9%, 98.2%, 84.9%, respectively. Results showed that the most serious adverse event was GI perforation (8.83 points, 10 being the most serious), whereas the least serious was anemia (5.32 points). There were significant differences among oncologists, nurses and pharmacists especially for the moderately-serious adverse event such as wound-healing complication and lymphopenia. Adverse Events Composite Score (AECS) for each targeted therapy was calculated by multiplying adverse event incidence rate and seriousness score. Sunitinib had the highest score at 6.86point and bevacizumab had the lowest at 2.1. Among professional groups oncologists showed the lowest AECS,whereas nurses had the highest. The gap on the perception of the adverse events among medical professionals needs to be reduced to get better outcomes of medical therapies for cancer patients.
목차
등록된 정보가 없습니다.
참고문헌 (10)
참고문헌 신청
Escudier B / 2007 / Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial / Lancet 370 : 2103 ~ 211
Hudes G / 2007 / Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma / N Engl J Med 356 : 2271 ~ 2281
Hutson TE / 2008 / Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies / Oncologist 13 : 1084 ~ 1096
McDermott DF / 2007 / Update on the application of interleukin-2 in the treatment of renal cell carcinoma / Clin Cancer Res 13 : 716s ~ 720s
Mickisch G / 2010 / Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compa
Hudes G / 2007 / Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma / N Engl J Med 356 : 2271 ~ 2281
Hutson TE / 2008 / Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies / Oncologist 13 : 1084 ~ 1096
McDermott DF / 2007 / Update on the application of interleukin-2 in the treatment of renal cell carcinoma / Clin Cancer Res 13 : 716s ~ 720s
Mickisch G / 2010 / Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compa
이 논문의 저자 정보
최근 본 자료
댓글(0)
0